News Notes

From left, Mike Karberg, Alan Lambowitz, and Huatao Guo Usually considered useless stretches of bases, introns are removed from RNA before it is translated into a protein. Now Alan Lambowitz, director of the Institute for Cellular and Molecular Biology at the University of Texas, and his colleagues have put group II introns to good use (H. Guo et al., "Group II introns designed to insert into therapeutically relevant DNA target sites in human cells," Science, 289:452-7, July 21, 2000). Eventual

Written byNadia Halim
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

From left, Mike Karberg, Alan Lambowitz, and Huatao Guo Usually considered useless stretches of bases, introns are removed from RNA before it is translated into a protein. Now Alan Lambowitz, director of the Institute for Cellular and Molecular Biology at the University of Texas, and his colleagues have put group II introns to good use (H. Guo et al., "Group II introns designed to insert into therapeutically relevant DNA target sites in human cells," Science, 289:452-7, July 21, 2000). Eventually the researchers hope to use introns instead of gene therapy vectors to introduce beneficial genes or disrupt harmful genes in patients. Excised group II introns, found only in bacteria and in organelles of plants, yeast, and fungi, exist in a ribonucleoprotein (RNP) complex with a reverse transcriptase protein that is encoded by the intron. With the help of the RNP complex and cellular machinery, the excised intron RNA inserts directly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies